TABLE 2.
Characteristics of 180 immunocompromised patients with a positive qPCR test for T. gondii (13 centers)
| Basis of analysis | No. (%) with positive qPCR |
P valuei | |||||
|---|---|---|---|---|---|---|---|
| HIV+ patients (n = 68) | HSCT patients (n = 72) | SOT patientsa |
Otherb (n = 26) | ||||
| Heart (n = 4) | Kidney (n = 7) | Liver (n = 3) | |||||
| Clinical diagnosis | <0.0001 | ||||||
| Cerebral toxoplasmosis | 44 (65) | 12 (16.5) | 0 | 4 (57) | 0 | 6 (23) | <0.0001 |
| Disseminated toxoplasmosis | 8 (12) | 30 (41.5) | 2 (50) | 2 (29) | 2 (67) | 9 (35) | 0.007** |
| Ocular toxoplasmosis | 15 (22) | 2 (3) | 0 | 0 | 0 | 9 (35) | <0.0001 |
| Isolated fever | 1 (1) | 5 (7) | 0 | 1 (14) | 0 | 2 (7) | 0.409 (NS) |
| Asymptomatic | 0 | 23 (32) | 2 (50) | 0 | 1 (33) | 0 | <0.0001 |
| No. of cases/no. of grafts (%)c | NAh | 71/2,220 (3.2)d; 1/2,940 (0.03)e | 4/282 (1.4) | 7/3,180 (0.2) | 3/1,896 (0.16) | NA | NA |
| No. of symptomatic cases/no. of grafts (%) | NA | 48/2,220 (2.2)d; 1/2,940 (0.03)e | 2/282 (0.7) | 7/3,180 (0.2) | 2/1,896 (0.11) | NA | NA |
| Chemoprophylaxis [no. (%)] | |||||||
| Yes | 4 (6) | 14 (19) | 1 (25) | 0 | 0 | 0 | NA |
| No | 17 (25) | 37 (51) | 3 (75) | 6 (86) | 2 (67) | 13 (50) | NA |
| Unknown | 47 (69) | 21 (29) | 0 | 1 (14) | 1 (33) | 13 (50) | NA |
| Treatment [no. (%)] | 0.0075** | ||||||
| Yes | 64 (94) | 54 (75) | 2 (50) | 7 (100) | 2 (67) | 18 (69) | |
| No | 0 | 13 (18) | 2 (50) | 0 | 1 (33) | 2 (8) | |
| Unknown | 4 (6) | 5 (7) | 0 | 0 | 0 | 6 (23) | |
| Outcome [no. (%)] | 0.626 (NS) | ||||||
| Survival at 2 mo | 53 (78) | 56 (78)f | 4 (100) | 4 (57) | 2 (67) | 18 (69)g | |
| Death | 11 (16) | 16 (22) | 0 | 3 (43) | 1 (33) | 7 (27) | |
| Unknown | 4 (6) | 0 | 0 | 0 | 0 | 1 (4) | |
Recipients were seropositive for Toxoplasma prior to transplantation in 7/14 cases.
Consisting of patients with hematological malignancies (16), connective tissue diseases receiving immunosuppressive drugs (5), solid tumors (2), congenital immunodeficiencies (2), or chronic alcoholism (1).
Based on cumulative data from all centers during the study period.
Data are for allo-HSCT patients.
Data are for auto-HSCT patients.
Survival was 67% when asymptomatic patients detected through systematic screening were excluded (P < 0.05, compared to HIV+ patients).
Survival was 53% when patients with ocular toxoplasmosis were excluded (P < 0.05, compared to HIV+ patients).
NA, not applicable.
Variables were compared using chi-square or Fisher exact tests. **, P < 0.01; NS, not significant.